COVID-19: biomedical perspectives:
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
London ; Oxford ; San Diego, CA ; Cambridge, MA
Academic Press, an imprint of Elsevier
2022
|
| Ausgabe: | First edition |
| Schriftenreihe: | Methods in microbiology
volume 50 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | vvii, 279 Seiten Illustrationen, Diagramme |
| ISBN: | 9780323850612 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV048318111 | ||
| 003 | DE-604 | ||
| 005 | 20220720 | ||
| 007 | t | ||
| 008 | 220707s2022 xxka||| |||| 00||| eng d | ||
| 020 | |a 9780323850612 |9 978-0-323-85061-2 | ||
| 035 | |a (OCoLC)1333080860 | ||
| 035 | |a (DE-599)BVBBV048318111 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a xxk |c XA-GB | ||
| 049 | |a DE-355 | ||
| 084 | |a WC 5700 |0 (DE-625)148117: |2 rvk | ||
| 084 | |a YD 8687 |0 (DE-625)164057:12996 |2 rvk | ||
| 245 | 1 | 0 | |a COVID-19: biomedical perspectives |c edited by Charles S. Pavia (Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury; Division of Infectious Deseases, New York Medical College, Valhalla, NY, United States), Volker Gurtler (School of Science, College of Science Engineering and Health, RMIT University, Bundoora, VIC, Australia) |
| 250 | |a First edition | ||
| 264 | 1 | |a London ; Oxford ; San Diego, CA ; Cambridge, MA |b Academic Press, an imprint of Elsevier |c 2022 | |
| 300 | |a vvii, 279 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Methods in microbiology |v volume 50 | |
| 650 | 0 | 7 | |a Nachweis |0 (DE-588)4115334-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a COVID-19 |0 (DE-588)1206347392 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Impfstoff |0 (DE-588)4026655-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Immunreaktion |0 (DE-588)4133841-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a COVID-19 |0 (DE-588)1206347392 |D s |
| 689 | 0 | 1 | |a Nachweis |0 (DE-588)4115334-0 |D s |
| 689 | 0 | 2 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | 3 | |a Immunreaktion |0 (DE-588)4133841-8 |D s |
| 689 | 0 | 4 | |a Impfstoff |0 (DE-588)4026655-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Pavia, Charles S. |0 (DE-588)1208773070 |4 edt | |
| 700 | 1 | |a Gurtler, Volker |0 (DE-588)1179720652 |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-0-323-85340-8 |
| 830 | 0 | |a Methods in microbiology |v volume 50 |w (DE-604)BV000899780 |9 50 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg - ADAM Catalogue Enrichment |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033697529&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033697529 | ||
Datensatz im Suchindex
| _version_ | 1804184173589561344 |
|---|---|
| adam_text | Contents Dedication....................................................................................................................... v Contributors................................................................................................................. xiii Preface......................... xvii CHAPTER 1 Sensitive methods for detection of SARS-CoV-2 RNA................................. 1 Xi Chen and Simin Xia 1, Introduction............................................................. 1 2. General approaches for the detection of SARS-CoV-2.....................3 3. Isothermal amplification methods for sensitive detection of SARS-CoV-2....................................................................................4 4. Sensitive detection of SARS-CoV-2 via RT-RPA.............................5 5. General considerations for designing an ultrasensitive RT-RPA assay................................................................................ 11 5.1 Primer design................................................................................ 11 5.2 Probe design..................................................................................12 5.3 Reaction temperature................................................................... 12 6. Comparative reviews of recently published RT-RPA assays for SARS-CoV-2 detection........................................................... 12 7. Methods section................................................................................... 17 8. Before you begin............................................................
17 9. Key resources table............................................................................. 17 10. Materials and equipment..................................................................... 19 11. Step-by-step method details................................................................ 19 11.1 Detection of SARS-CoV-2 N- or S-gene using exo probes and primers....................... .................................... 19 11.2 Detection of SARS-CoV-2 N- or S-gene using nfo probes and lateral flow strips.......................................... 21 11.3 Optional steps............................................................................ 22 11.4 Simultaneous dual N- and S-gene detection using paired exo probe and primers for N-gene and exo probe and primers for S-gene............................................................ 22 12. Summary.............................................................................................. 23 Acknowledgement...................................................................................... 24 References.... ............................................................................................... 24 vii
viii Contents CHAPTER 2 The seasonal behaviour of COVID-19 and its galectin-like culprit of the viral spike..... 27 Kelsey Caetano-Anollés, Nicolas Hernandez, Fizza Mughal, Tre Tomaszewski, and Gustavo Caetano-Anollés 1. Introduction.......................................................................................... 27 2. The seasonal behaviour of viruses.....................................................28 2.1 Seasonality of viral diseases....................................................... 28 2.2 Drivers of seasonality in trade-off performance spaces..........31 2.3 Finding significant correlations.................................................. 36 2.4 Distinguishing error from chaos in time series.........................37 3. The seasonal behaviour of COVID-19..............................................40 3.1 Spatial distribution approaches..................................................42 3.2 Temporal distribution approaches............................................. 45 4. Viral genomic make up and seasonality........................................... 46 4.1 Mutational change in rapidly expanding viral populations.... 49 4.2 A structuring quasispecies as paradigm of viral mutational change........................................................................ 51 4.3 The mutational landscape of evolving SARS-CoV-2 viruses.......................................................................................... .53 4.4 Viral genomic change and seasonal behaviour........................60 4.5 Genomic change levels appear unlinked to temperature or
latitude.......................... 63 4.6 Galectin homologues appear likely molecular culprits............64 5. Conclusions and prospects..................................................................68 Acknowledgements................................... 69 Financial disclosures and conflicts of interest....................................... 69 References............................................................ 69 Further reading.......................................................................................... 79 Glossary...................................................................................................... 79 CHAPTER 3 Current molecular diagnostics assays for SARS-CoV-2 and emerging variants............................... 83 Jonathan Μ. Banks, Kristalle Capistrano, Pari Thakkar, Hemangi Ranade, Vaidik Soni, Manali Datta, and Afsar R. Naqvi 1. Introduction.........................................................................................84 2. SARS-CoV-2 variants of concern.................................................... 85 2.1 В. 1.1.7 (Alpha) variant................................................................ 88 2.2 B.1.351 (Beta) variant................................................................. 88 2.3 P.l (Gamma) variant..................................... 90 2.4 B.1.617.2 (Delta) variant............................................................. 90
Contents 3. COVID-19 diagnostics....................................................................... 91 3.1 Real-time PCR diagnostics......................................................... 92 3.2 Serology based COVID-19 diagnostics..................................... 97 3.3 CRISPR diagnostics................................................................... 101 3.4 Biosensor diagnostics................................................................ 103 4. Diagnostics in the era of COVID-19 vaccination.......................... 109 5. Conclusion......................................................................................... Ill References............................................................................................... 112 Further reading........................................................................................ 120 CHAPTER 4 CRISPR use in diagnosis and therapy for COVID-19...123 Fallavi Deol, Aashwina Madhwal, Gaurav Sharma, Rahul Kaushik, and Yashpal Singh Malik 1. Introduction...................................................................................... 124 2. Diagnostics and therapeutics for SARS-CoV-2............................ 125 3. CRISPR/Cas systems....................................................................... 127 3.1 Casl2........................................................................................... 128 4. CRISPR-based therapeutics for SARS-Cov-2.............................. 136 4.1 Disrupting the viral RNA genome........................................... 137 4.2 Disrupting the host cell
factors essential for SARS-CoV-2 infection.......................................................143 5. Delivery of CRISPR/Cas components........................................... 144 6. Limitations of CRISPR/Cas system............................................... 144 7. Summary........................................................................ 145 References................................................................................................146 CHAPTER 5 Recent and advanced nano-technological strategies for COVID-19 vaccine development........... 151 Chinekwu Sherridan Nwagwu, Chinenye Nnenna Ugwu, John Dike Nwabueze Ogbonna, Adaeze Linda Onugwu, Chinazom Precious Agbo, Adaeze Chidiebere Echezona, Ezinwanne Nneoma Ezeibe, Samuel Uzondu, Frankline Chimaobi Kenechukwu, Paul Achile Акра, Mumuni Audu Momoh, Petra Obioma Nnamani, Clemence Tarirai, Kenneth Chibuzor Ofokansi, and Anthony Amaechi Attama 1. Introduction........................................................................................ 151 2. The structure and infection mechanism of SARS-COV-2........... 152 3. Pathogenesis and clinical presentation of COVID-19................... 153 ix
x Contents 4. Vaccine development strategies and platforms.............................. 155 4.1 Live attenuated viral vaccines.................................................. 156 4.2 Inactivated pathogen vaccines.................................................. 158 4.3 Protein subunit vaccines............................................................ 163 4.4 Virus-like particle vaccines....................................................... 164 4.5 Vectored vaccines........................................................ 164 4.6 Nucleic acid vaccines.................................................................165 5. Relevant SARS-CoV-2 antigen explored in the design of vaccines.............................................................................................. 166 5.1 Structural, sub-structural, and non-structural proteins........... 166 5.2 Spike (S) pyptein.........................................................................166 5.3 Membrane (Μ) protein.............................................................. 169 5.4 Nucleocapsid (N) protein.......................................................... 169 5.5 Envelop (E) protein........................ 170 6. Nano-based strategies for COVID-19 vaccine development....... 170 6.1 Nano-carriers for antigen delivery............................................171 6.2 Nano-vaccine adjuvants............................................................. 174 6.3 Delivery devices......................................................................... 175 6.4 Novel alternative routes of
administration.............................. 176 7. Benefits and challenges of nanotechnology in COVID-19 vaccine development.................... ................................................... 178 8. Conclusion and futureperspectives.................................................. 179 References................................................................................................ 180 CHAPTER 6 A review of hypersensitivity methods to detect immune responses toSARS-CoV-2.......................... 1Д9 Fernando Diaz-Espada, Victor Matheu, and Yvelise Barrios 1. Historical perspective....................................................................... 190 2. General overview, classification and description of hypersensitivity reactions.................................................................193 2.1 Type I hypersensitivity-immediateÆgE mediated.............. . 193 2.2 Type II hypersensitivity-ІІаДІЬ antibody mediated... ........... 196 2.3 Type ІП hypersensitivity-immune complex-mediated.......... 198 2.4 Type IV hypersensitivity-IVa/IVbJVcnVd-T cell mediated...................................................................................... 200 3. Skin test application of hypersensitivity reactions: In vivo measurements of immune responses......................................... 205 4. In vitro methods to measure immune responses after SARS-Cov-2 infection...................................................................... 206 4.1 SARS-CoV-2 protein description................ ............................ 206
Contents 4.2 Understanding the adaptive immune response in covidl9 patients................................................................................ 207 4.3 In vitro methods to measure SARS-CoV-2 cellular immune responses............................................................. 209 5. A novel application of a DTH method to measure immune responses after SARS-CoV-2 infection....................................211 6. DTH to measure immunogenicity elicited by covid vaccines.....213 7. Future prospects of DTH to study SARS-CoV-2 immunogenicity.................................................................................214 Acknowledgements................................................................................ 214 References............................................................................................... 214 CHAPTER 7 Hesitancy to get vaccinated against COVID-19 and how it might be overcome............. 223 Charles S. Pavia CHAPTER 8 The emergence of SARS-CoV-2 variants of concern in Australia by haplotype coalescence reveals a continental link to COVID-19 seasonality................ 233 Tre Tomaszewski, Volker Gürtler, Kelsey Caetano-Anollés, and Gustavo Caetano-Anollés 1. 2. 3. 4. Introduction........................................................................................ 233 Methods........................................................................... 235 VOCs in Australia............................................................................. 236 Prevalence of amino acid variants in Australia.............................
240 4.1 The emergence of first haplotypes........................................... 240 4.2 Emergence of haplotypes associated with VOCs alpha, delta and omicron..................................... 243 4.3 Amino acid variants and haplotypes shared by VOCs......... 245 4.4 Amino acid variants that are not part of established VOC constellations.............................................................................. 246 5. A network view of haplotype diversity and VOC emergence.....246 5.1 Haplotype and variant reuse....... ........................................ 246 5.2 Haplotype size and coalescence............................................... 249 5.3 Haplotypes and protein interactions........................................ 249 5.4 VOC omicron haplotype variants cluster along the S-protein sequence.................................................................... 251 5.5 Haplotypes follow the three phases of the COVID-19 pandemic.............................................................................253 xi
xii Contents 6. Continental links to seasonality....................................................... 254 6.1 Core haplotypes of VOCs reveal latitude-linked patterns of seasonality...................................................................... 254 6.2 Free-standing markers also support seasonal behavior in Australia.............................................................................. 256 7. Discussion................................................................................. 258 7.1 Mutational landscapes of viral evolution................................ 260 7.2 VOC emergence by haplotype coalescence............................ 261 7.3 Haplotypes and seasonal behavior........................................... 262 7.4 Conclusions................................................................................ 264 References................................................................................................265 •« CHAPTER 9 COVID-19 vaccines for high risk and immunocompromised patients.............. 269 Charles S. Pavia and Maria Μ. Plummer 1. Introduction........................................................................................ 269 2. Development of COVID-19 vaccines............................................. 270 3. The use of COVID-19 vaccines for the high-risk patient population with the emphasison HIV-infected patients........ .272 Funding.................................................. ................................................ 277 Author
contribution.................................................................................277 Conflict of interest.................................................. References................................................................... ............................ 277 ar 2
|
| adam_txt |
Contents Dedication. v Contributors. xiii Preface. xvii CHAPTER 1 Sensitive methods for detection of SARS-CoV-2 RNA. 1 Xi Chen and Simin Xia 1, Introduction. 1 2. General approaches for the detection of SARS-CoV-2.3 3. Isothermal amplification methods for sensitive detection of SARS-CoV-2.4 4. Sensitive detection of SARS-CoV-2 via RT-RPA.5 5. General considerations for designing an ultrasensitive RT-RPA assay. 11 5.1 Primer design. 11 5.2 Probe design.12 5.3 Reaction temperature. 12 6. Comparative reviews of recently published RT-RPA assays for SARS-CoV-2 detection. 12 7. Methods section. 17 8. Before you begin.
17 9. Key resources table. 17 10. Materials and equipment. 19 11. Step-by-step method details. 19 11.1 Detection of SARS-CoV-2 N- or S-gene using exo probes and primers. . 19 11.2 Detection of SARS-CoV-2 N- or S-gene using nfo probes and lateral flow strips. 21 11.3 Optional steps. 22 11.4 Simultaneous dual N- and S-gene detection using paired exo probe and primers for N-gene and exo probe and primers for S-gene. 22 12. Summary. 23 Acknowledgement. 24 References. . 24 vii
viii Contents CHAPTER 2 The seasonal behaviour of COVID-19 and its galectin-like culprit of the viral spike. 27 Kelsey Caetano-Anollés, Nicolas Hernandez, Fizza Mughal, Tre Tomaszewski, and Gustavo Caetano-Anollés 1. Introduction. 27 2. The seasonal behaviour of viruses.28 2.1 Seasonality of viral diseases. 28 2.2 Drivers of seasonality in trade-off performance spaces.31 2.3 Finding significant correlations. 36 2.4 Distinguishing error from chaos in time series.37 3. The seasonal behaviour of COVID-19.40 3.1 Spatial distribution approaches.42 3.2 Temporal distribution approaches. 45 4. Viral genomic make up and seasonality. 46 4.1 Mutational change in rapidly expanding viral populations. 49 4.2 A structuring quasispecies as paradigm of viral mutational change. 51 4.3 The mutational landscape of evolving SARS-CoV-2 viruses. .53 4.4 Viral genomic change and seasonal behaviour.60 4.5 Genomic change levels appear unlinked to temperature or
latitude. 63 4.6 Galectin homologues appear likely molecular culprits.64 5. Conclusions and prospects.68 Acknowledgements. 69 Financial disclosures and conflicts of interest. 69 References. 69 Further reading. 79 Glossary. 79 CHAPTER 3 Current molecular diagnostics assays for SARS-CoV-2 and emerging variants. 83 Jonathan Μ. Banks, Kristalle Capistrano, Pari Thakkar, Hemangi Ranade, Vaidik Soni, Manali Datta, and Afsar R. Naqvi 1. Introduction.84 2. SARS-CoV-2 variants of concern. 85 2.1 В. 1.1.7 (Alpha) variant. 88 2.2 B.1.351 (Beta) variant. 88 2.3 P.l (Gamma) variant. 90 2.4 B.1.617.2 (Delta) variant. 90
Contents 3. COVID-19 diagnostics. 91 3.1 Real-time PCR diagnostics. 92 3.2 Serology based COVID-19 diagnostics. 97 3.3 CRISPR diagnostics. 101 3.4 Biosensor diagnostics. 103 4. Diagnostics in the era of COVID-19 vaccination. 109 5. Conclusion. Ill References. 112 Further reading. 120 CHAPTER 4 CRISPR use in diagnosis and therapy for COVID-19.123 Fallavi Deol, Aashwina Madhwal, Gaurav Sharma, Rahul Kaushik, and Yashpal Singh Malik 1. Introduction. 124 2. Diagnostics and therapeutics for SARS-CoV-2. 125 3. CRISPR/Cas systems. 127 3.1 Casl2. 128 4. CRISPR-based therapeutics for SARS-Cov-2. 136 4.1 Disrupting the viral RNA genome. 137 4.2 Disrupting the host cell
factors essential for SARS-CoV-2 infection.143 5. Delivery of CRISPR/Cas components. 144 6. Limitations of CRISPR/Cas system. 144 7. Summary. 145 References.146 CHAPTER 5 Recent and advanced nano-technological strategies for COVID-19 vaccine development. 151 Chinekwu Sherridan Nwagwu, Chinenye Nnenna Ugwu, John Dike Nwabueze Ogbonna, Adaeze Linda Onugwu, Chinazom Precious Agbo, Adaeze Chidiebere Echezona, Ezinwanne Nneoma Ezeibe, Samuel Uzondu, Frankline Chimaobi Kenechukwu, Paul Achile Акра, Mumuni Audu Momoh, Petra Obioma Nnamani, Clemence Tarirai, Kenneth Chibuzor Ofokansi, and Anthony Amaechi Attama 1. Introduction. 151 2. The structure and infection mechanism of SARS-COV-2. 152 3. Pathogenesis and clinical presentation of COVID-19. 153 ix
x Contents 4. Vaccine development strategies and platforms. 155 4.1 Live attenuated viral vaccines. 156 4.2 Inactivated pathogen vaccines. 158 4.3 Protein subunit vaccines. 163 4.4 Virus-like particle vaccines. 164 4.5 Vectored vaccines. 164 4.6 Nucleic acid vaccines.165 5. Relevant SARS-CoV-2 antigen explored in the design of vaccines. 166 5.1 Structural, sub-structural, and non-structural proteins. 166 5.2 Spike (S) pyptein.166 5.3 Membrane (Μ) protein. 169 5.4 Nucleocapsid (N) protein. 169 5.5 Envelop (E) protein. 170 6. Nano-based strategies for COVID-19 vaccine development. 170 6.1 Nano-carriers for antigen delivery.171 6.2 Nano-vaccine adjuvants. 174 6.3 Delivery devices. 175 6.4 Novel alternative routes of
administration. 176 7. Benefits and challenges of nanotechnology in COVID-19 vaccine development. . 178 8. Conclusion and futureperspectives. 179 References. 180 CHAPTER 6 A review of hypersensitivity methods to detect immune responses toSARS-CoV-2. 1Д9 Fernando Diaz-Espada, Victor Matheu, and Yvelise Barrios 1. Historical perspective. 190 2. General overview, classification and description of hypersensitivity reactions.193 2.1 Type I hypersensitivity-immediateÆgE mediated. . 193 2.2 Type II hypersensitivity-ІІаДІЬ antibody mediated. . 196 2.3 Type ІП hypersensitivity-immune complex-mediated. 198 2.4 Type IV hypersensitivity-IVa/IVbJVcnVd-T cell mediated. 200 3. Skin test application of hypersensitivity reactions: In vivo measurements of immune responses. 205 4. In vitro methods to measure immune responses after SARS-Cov-2 infection. 206 4.1 SARS-CoV-2 protein description. . 206
Contents 4.2 Understanding the adaptive immune response in covidl9 patients. 207 4.3 In vitro methods to measure SARS-CoV-2 cellular immune responses. 209 5. A novel application of a DTH method to measure immune responses after SARS-CoV-2 infection.211 6. DTH to measure immunogenicity elicited by covid vaccines.213 7. Future prospects of DTH to study SARS-CoV-2 immunogenicity.214 Acknowledgements. 214 References. 214 CHAPTER 7 Hesitancy to get vaccinated against COVID-19 and how it might be overcome. 223 Charles S. Pavia CHAPTER 8 The emergence of SARS-CoV-2 variants of concern in Australia by haplotype coalescence reveals a continental link to COVID-19 seasonality. 233 Tre Tomaszewski, Volker Gürtler, Kelsey Caetano-Anollés, and Gustavo Caetano-Anollés 1. 2. 3. 4. Introduction. 233 Methods. 235 VOCs in Australia. 236 Prevalence of amino acid variants in Australia.
240 4.1 The emergence of first haplotypes. 240 4.2 Emergence of haplotypes associated with VOCs alpha, delta and omicron. 243 4.3 Amino acid variants and haplotypes shared by VOCs. 245 4.4 Amino acid variants that are not part of established VOC constellations. 246 5. A network view of haplotype diversity and VOC emergence.246 5.1 Haplotype and variant reuse. . 246 5.2 Haplotype size and coalescence. 249 5.3 Haplotypes and protein interactions. 249 5.4 VOC omicron haplotype variants cluster along the S-protein sequence. 251 5.5 Haplotypes follow the three phases of the COVID-19 pandemic.253 xi
xii Contents 6. Continental links to seasonality. 254 6.1 Core haplotypes of VOCs reveal latitude-linked patterns of seasonality. 254 6.2 Free-standing markers also support seasonal behavior in Australia. 256 7. Discussion. 258 7.1 Mutational landscapes of viral evolution. 260 7.2 VOC emergence by haplotype coalescence. 261 7.3 Haplotypes and seasonal behavior. 262 7.4 Conclusions. 264 References.265 •« CHAPTER 9 COVID-19 vaccines for high risk and immunocompromised patients. 269 Charles S. Pavia and Maria Μ. Plummer 1. Introduction. 269 2. Development of COVID-19 vaccines. 270 3. The use of COVID-19 vaccines for the high-risk patient population with the emphasison HIV-infected patients. .272 Funding. . 277 Author
contribution.277 Conflict of interest. References. . 277 ar 2 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author2 | Pavia, Charles S. Gurtler, Volker |
| author2_role | edt edt |
| author2_variant | c s p cs csp v g vg |
| author_GND | (DE-588)1208773070 (DE-588)1179720652 |
| author_facet | Pavia, Charles S. Gurtler, Volker |
| building | Verbundindex |
| bvnumber | BV048318111 |
| classification_rvk | WC 5700 YD 8687 |
| ctrlnum | (OCoLC)1333080860 (DE-599)BVBBV048318111 |
| discipline | Biologie Medizin |
| discipline_str_mv | Biologie Medizin |
| edition | First edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02469nam a2200505 cb4500</leader><controlfield tag="001">BV048318111</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20220720 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">220707s2022 xxka||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780323850612</subfield><subfield code="9">978-0-323-85061-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1333080860</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048318111</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxk</subfield><subfield code="c">XA-GB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WC 5700</subfield><subfield code="0">(DE-625)148117:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YD 8687</subfield><subfield code="0">(DE-625)164057:12996</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COVID-19: biomedical perspectives</subfield><subfield code="c">edited by Charles S. Pavia (Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury; Division of Infectious Deseases, New York Medical College, Valhalla, NY, United States), Volker Gurtler (School of Science, College of Science Engineering and Health, RMIT University, Bundoora, VIC, Australia)</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London ; Oxford ; San Diego, CA ; Cambridge, MA</subfield><subfield code="b">Academic Press, an imprint of Elsevier</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">vvii, 279 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Methods in microbiology</subfield><subfield code="v">volume 50</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nachweis</subfield><subfield code="0">(DE-588)4115334-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">COVID-19</subfield><subfield code="0">(DE-588)1206347392</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Immunreaktion</subfield><subfield code="0">(DE-588)4133841-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">COVID-19</subfield><subfield code="0">(DE-588)1206347392</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Nachweis</subfield><subfield code="0">(DE-588)4115334-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Immunreaktion</subfield><subfield code="0">(DE-588)4133841-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pavia, Charles S.</subfield><subfield code="0">(DE-588)1208773070</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gurtler, Volker</subfield><subfield code="0">(DE-588)1179720652</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-0-323-85340-8</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Methods in microbiology</subfield><subfield code="v">volume 50</subfield><subfield code="w">(DE-604)BV000899780</subfield><subfield code="9">50</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg - ADAM Catalogue Enrichment</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033697529&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033697529</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV048318111 |
| illustrated | Illustrated |
| index_date | 2024-07-03T20:11:12Z |
| indexdate | 2024-07-10T09:35:08Z |
| institution | BVB |
| isbn | 9780323850612 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033697529 |
| oclc_num | 1333080860 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | vvii, 279 Seiten Illustrationen, Diagramme |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | Academic Press, an imprint of Elsevier |
| record_format | marc |
| series | Methods in microbiology |
| series2 | Methods in microbiology |
| spelling | COVID-19: biomedical perspectives edited by Charles S. Pavia (Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury; Division of Infectious Deseases, New York Medical College, Valhalla, NY, United States), Volker Gurtler (School of Science, College of Science Engineering and Health, RMIT University, Bundoora, VIC, Australia) First edition London ; Oxford ; San Diego, CA ; Cambridge, MA Academic Press, an imprint of Elsevier 2022 vvii, 279 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Methods in microbiology volume 50 Nachweis (DE-588)4115334-0 gnd rswk-swf COVID-19 (DE-588)1206347392 gnd rswk-swf Impfstoff (DE-588)4026655-2 gnd rswk-swf Immunreaktion (DE-588)4133841-8 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content COVID-19 (DE-588)1206347392 s Nachweis (DE-588)4115334-0 s Therapie (DE-588)4059798-2 s Immunreaktion (DE-588)4133841-8 s Impfstoff (DE-588)4026655-2 s DE-604 Pavia, Charles S. (DE-588)1208773070 edt Gurtler, Volker (DE-588)1179720652 edt Erscheint auch als Online-Ausgabe 978-0-323-85340-8 Methods in microbiology volume 50 (DE-604)BV000899780 50 Digitalisierung UB Regensburg - ADAM Catalogue Enrichment application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033697529&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | COVID-19: biomedical perspectives Methods in microbiology Nachweis (DE-588)4115334-0 gnd COVID-19 (DE-588)1206347392 gnd Impfstoff (DE-588)4026655-2 gnd Immunreaktion (DE-588)4133841-8 gnd Therapie (DE-588)4059798-2 gnd |
| subject_GND | (DE-588)4115334-0 (DE-588)1206347392 (DE-588)4026655-2 (DE-588)4133841-8 (DE-588)4059798-2 (DE-588)4143413-4 |
| title | COVID-19: biomedical perspectives |
| title_auth | COVID-19: biomedical perspectives |
| title_exact_search | COVID-19: biomedical perspectives |
| title_exact_search_txtP | COVID-19: biomedical perspectives |
| title_full | COVID-19: biomedical perspectives edited by Charles S. Pavia (Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury; Division of Infectious Deseases, New York Medical College, Valhalla, NY, United States), Volker Gurtler (School of Science, College of Science Engineering and Health, RMIT University, Bundoora, VIC, Australia) |
| title_fullStr | COVID-19: biomedical perspectives edited by Charles S. Pavia (Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury; Division of Infectious Deseases, New York Medical College, Valhalla, NY, United States), Volker Gurtler (School of Science, College of Science Engineering and Health, RMIT University, Bundoora, VIC, Australia) |
| title_full_unstemmed | COVID-19: biomedical perspectives edited by Charles S. Pavia (Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury; Division of Infectious Deseases, New York Medical College, Valhalla, NY, United States), Volker Gurtler (School of Science, College of Science Engineering and Health, RMIT University, Bundoora, VIC, Australia) |
| title_short | COVID-19: biomedical perspectives |
| title_sort | covid 19 biomedical perspectives |
| topic | Nachweis (DE-588)4115334-0 gnd COVID-19 (DE-588)1206347392 gnd Impfstoff (DE-588)4026655-2 gnd Immunreaktion (DE-588)4133841-8 gnd Therapie (DE-588)4059798-2 gnd |
| topic_facet | Nachweis COVID-19 Impfstoff Immunreaktion Therapie Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033697529&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000899780 |
| work_keys_str_mv | AT paviacharless covid19biomedicalperspectives AT gurtlervolker covid19biomedicalperspectives |